A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma

[1]  P. Gaulard,et al.  Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  N. Ifrah,et al.  Intensive therapies in follicular non-Hodgkin lymphomas. , 2002, Blood.

[3]  B. Emmerich,et al.  The CD19+ B‐cell counts at peripheral blood stem cell mobilization determine different levels of tumour contamination and autograft purgability in low‐grade lymphoma , 2002, British journal of haematology.

[4]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[5]  L. Arcaini,et al.  A sequence of immuno‐chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high‐dose chemotherapy and autotransplant is an effective 
and non‐toxic treatment for advanced follicular 
and mantle cell lymphoma , 2002, British journal of haematology.

[6]  J. Vose,et al.  Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  I. Flinn,et al.  Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  A. Pileri,et al.  Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion , 2000 .

[9]  V. Zagonel,et al.  Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. , 2000, Therapeutic drug monitoring.

[10]  M. Voso,et al.  In vivo depletion of B cells using a combination of high‐dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non‐Hodgkin's lymphoma , 2000, British journal of haematology.

[11]  A. Pileri,et al.  Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft , 2000, Leukemia.

[12]  J. Gribben,et al.  Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. , 1999, Blood.

[13]  D. Spaner,et al.  Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. , 1999, Seminars in oncology.

[14]  M. Czuczman,et al.  Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  E. González-Barca,et al.  Immunomagnetic bone marrow (BM) and peripheral blood progenitor cell (PBPC) purging in follicular lymphoma (FL) , 1999, Bone Marrow Transplantation.

[16]  L. Gordon,et al.  Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  V. Diehl,et al.  Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. , 1998, Blood.

[18]  M. Labopin,et al.  Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Perreault,et al.  Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources. , 1998, Blood.

[21]  N. Schmitz,et al.  Purging Peripheral Blood Progenitor Cell Grafts from Lymphoma Cells: Quantitative Comparison of Immunomagnetic CD34+ Selection Systems , 1997, Stem cells.

[22]  N. Russell,et al.  Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular lymphoma: a pilot study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Demidem,et al.  Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. , 1997, Cancer biotherapy & radiopharmaceuticals.

[24]  I Royston,et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.

[25]  M. Deschaseaux,et al.  Comparative preclinical study of three bone marrow purging methods using PCR evaluation of residual t(14;18) lymphoma cells. , 1996, Leukemia & lymphoma.

[26]  D. Weisenburger,et al.  Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Gribben,et al.  Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. , 1993, Blood.

[28]  J. Gribben,et al.  All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. , 1991, Blood.